Bracco Diagnostics has achieved the milestone of one million patient injections of its MRI contrast agent gadopiclenol (Vueway) at more than 480 customer sites.
Vueway is a highly stable, macrocyclic gadolinium-based contrast agent that has higher relaxivity compared with other commercially available MRI contrast agents on the market, according to the vendor. The agent is indicated in adults and children aged two years and older for use MRI to detect and visualize lesions with abnormal vascularity in the central nervous system (brain, spine, and associated tissues) and the body (head and neck, thorax, abdomen, pelvis, and musculoskeletal system).
The one-millionth dose was injected at Tampa General Hospital in Florida, noted Ryan Murtagh, MD, the hospital’s chief of neuroradiology, in a news release.
